AlzeCure: Change of CEO as the company enters a new phase - Redeye
Bildkälla: Stockfoto

AlzeCure: Change of CEO as the company enters a new phase - Redeye

Redeye comments on AlzeCure's announcement that CEO Martin Jönsson is stepping down by mutual agreement with the Board. Co-founder and CSO Dr. Johan Sandin takes over as acting CEO, and Dr. Pontus Forsell, Head of Discovery & Research, becomes Deputy CEO while the Board recruits a permanent successor. Coming soon after the Eli Lilly and QuantumCell agreements, the Board presents the change as part of a shift in the company's focus.

Redeye comments on AlzeCure's announcement that CEO Martin Jönsson is stepping down by mutual agreement with the Board. Co-founder and CSO Dr. Johan Sandin takes over as acting CEO, and Dr. Pontus Forsell, Head of Discovery & Research, becomes Deputy CEO while the Board recruits a permanent successor. Coming soon after the Eli Lilly and QuantumCell agreements, the Board presents the change as part of a shift in the company's focus.
Börsvärldens nyhetsbrev